Blog
RSS FeedPosted by Michael Wonder on 03 Dec 2022
AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan
1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...
Posted by Michael Wonder on 03 Dec 2022
Hopes $55k breast cancer drug Keytruda will get PBS listing
3 December 2022 - Women with triple negative breast cancer have been given new hope that immunotherapy drug Keytruda will ...
Posted by Michael Wonder on 02 Dec 2022
Tezepelumab for the treatment of patients with severe asthma
2 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 02 Dec 2022
Agenda for the December 2022 PBAC intracycle meeting
2 December 2022 - The agenda for the December 2022 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 01 Dec 2022
Early breast cancer: indication of a minor additional clinical benefit of adjuvant therapy with olaparib
1 December 2022 - Adjuvant treatment with olaparib can prolong life and prevent recurrence in early breast cancer. However, it ...
Posted by Michael Wonder on 01 Dec 2022
‘Good news’ for Kiwi women as PHARMAC funds Utrogestan from today
1 December 2022 - The end of a decade long wait. ...
Posted by Michael Wonder on 01 Dec 2022
Livtencity (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus infection
1 December 2022 - The conditions for the positive recommendation is supported by the findings of the Phase 3 SOLSTICE ...
Posted by Michael Wonder on 01 Dec 2022
Lenvatinib mesylate in combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma
30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 01 Dec 2022
Reimbursed access to Bylvay (odevixibat) approved in France for patients with PFIC 1 & 2
30 November 2022 - Albireo Pharma today announced that the Committee Economic Health Products has approved reimbursed access to Bylvay (odevixibat) ...
Posted by Michael Wonder on 01 Dec 2022
Cemiplimab for the first-line treatment of patients wth advanced or metastatic PD-L1 positive non-small-cell lung cancer
1 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 30 Nov 2022
Schedule of Pharmaceutical Benefits - 1 December 2022
1 December 2022 - The December 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Nov 2022
New Zealand Pharmaceutical Schedule - 1 December 2022
1 December 2022 - The December 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Nov 2022
The Government may have taken money from the DHB hospital budget to increase PHARMAC's funding
30 November 2022 - In this year’s budget, the Government said it has increased PHARMAC's funding by 43% over the ...
Posted by Michael Wonder on 30 Nov 2022
Ripretinib for the treatment of patients with an advanced gastro-intestinal stromal tumour after three or more therapies
30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Nov 2022
Mepolizumab for the treatment of patients with severe chronic rhinosinusitis with nasal polyps
29 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...